Hemophilia and Bleeding Disorders
Hemophilia is a genetic disorder marked by prolonged bleeding due to a decrease or absence of one of the coagulation factors needed to form blood clots. Approximately 1 in 8,000 males is affected. Hemophilia is caused by a faulty gene that alters the body's ability to produce enough factor to cause clotting. In the most common types of hemophilia, either factor VIII (eight) or factor IX (nine) is missing.
von Willebrand disease (VWD) is a hereditary disorder characterized by abnormally slow clotting of the blood. Patients with von Willebrand disease may have spontaneous and prolonged bleeding from the nose and gums. VWD occurs in about 1 in 100 people and affects both males and females.
CSL Behring offers a wide range of plasma-derived and recombinant therapies and pharmaceuticals for the treatment of bleeding disorders. We also provide a variety of support services specially targeted to address the needs of people with bleeding disorders, their families, and their healthcare providers.
Hemophilia A
Hemophilia B
von Willebrand Disease
Events and Activities
Hemophilia Treatment Centers